CSI Market
Sign In | Register

Verona Pharma Plc (VRNA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access VRNA quarterly Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Verona Pharma Plc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2024)
12 Months 		(Dec 31 2023) (Dec 31 2022) (Dec 31 2021) (Dec 31 2020)
Operating Activities
Income-173.42
Depreciation & amortization1.06
Amortization of Other Assets0.12
Accretion Expense9.40
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories8.22
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation41.24
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction-0.17
Operating Lease Impairment Loss-
Increase Decrease In Tax And Tax Credit Receivables Current5.03
Increase Decrease In Operating Lease Liabilities-0.84
Increase Decrease In Equity Interest Receivable-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable31.50
Increase (Decrease) in Accounts Payable7.87
Increase (Decrease) in Accrued Liabilities12.82
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense3.96
Other Working Capital0.12
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities1.10
Discontinued operations0.00
Net Cash flow from Operating Activities-122.20
Investing Activities
Capital Expenditures0.58
Sale of Capital Items0.00
Proceeds from Sale of Held-to-maturity Securities0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.58
Financing Activities
Short-term debt Net0.00
Other borrowing transactions6.92
Long-term debt - borrowings122.50
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net15.45
Other net-287.23
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents271.77
Proceeds From Revenue Interest Purchase And Sale Agreement R I P S A100.00
Repurchase Of Revenue Interest Purchase And Sale Agreement R I P S A-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities250.78
Effect of exchange rate on cash flow-0.01
Discontinued operations0.00
Free Cash Flow-121.62
Total Cash Flow127.99
4 historic quarters locked

Sign in to unlock the full Verona Pharma Plc cash flow history.

Sign In Create Free Account

About Verona Pharma Plc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20241231)
  • Filed with the SEC: February 27, 2025
  • Source: vrna-20241231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001657312-25-000010

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License